biologic agents in rheumatology: a virtual reality tour ... · biologic agents in rheumatology: a...
TRANSCRIPT
Biologic Agents in Rheumatology: A Virtual Reality Tour through Psoriatic Arthritis and
Rheumatoid Arthritis
Joseph F. Merola, MD, MMSc
Assistant Professor, Harvard Medical SchoolDirector, Clinical Unit for Research Innovation and Trials (CUReIT), Dermatology
Co‐Director, Center for Skin and Related Musculoskeletal DiseasesDept of Dermatology and Dept of Medicine, Division of Rheumatology
Associate Program Director, Combined Medicine‐Dermatology Residency ProgramBrigham and Women's Hospital
Boston, MA
Disclosures Consultant for Biogen IDEC, AbbVie, Eli Lilly, Novartis, Pfizer, Janssen, UCB,
Samumed, Science 37, Celgene, Sanofi‐Genzyme / Regeneron and GSK. Investigator for Biogen IDEC, Pfizer, Sanofi Genzyme / Regeneron, Incyte,
Novartis. Licensed outcome measure to Abbvie and Lilly. Medical Board: National Psoriasis Foundation, Lupus Foundation of
America Steering Committee: GRAPPA Board of Directors: IDEOM (International Dermatology Outcome
Measures), PPACMAN Expert Panel: ACR PsA Guidelines
Several of the therapies reviewed in this presentation may involve off‐label use of medications
This activity is supported by an educational grant from Lilly.
Psoriatic Arthritis: Pathophysiology and Diagnosis
Psoriasis: Pathogenesis
• Immune dysregulation (TH‐1 and TH‐17)
• Inflammation– Cytokines
• Keratinocyte hyperproliferation
• Inflammatory/auto‐inflammatory disorder• Systemic disease
TH = T‐helper (cell)
(keratinocyte‐derived)ADAMTSL5 (melanocyte‐derived)
T cells
Psoriasis
Immunopathogenesis of Psoriasis
KC = keratinocyte; DC = dendritic cell; IL = interleukin; IFN = interferon; TNF = tumor necrosis factor; AMP = antimicrobial peptide.
Lowes MA et al. Annu Rev Immunol. 2014;32:227‐255. Lande R et al. Nat Commun. 2014;3(5):5621. Arakawa A et al. JEM. 2015;212(13):2203.
Insert virtual reality “how‐to” video
Insert video: Psoriatic Arthritis
Psoriatic Arthritis: Timing
• Usually skin changes/PsO before arthritis (70%)1
• Subset with skin and joints concurrently (15%)1
• Inflammatory joint symptoms prior to skin changes (15%)1
• Typical lag time of 7–10 years from the onset of psoriasis to diagnosis of PsA1,2
1. Anandarajah AP, Ritchlin CT. Nat Rev Rheumatol. 2009;5:634‐641. 2. Mease P, et al. Drugs. 2014;74(4):423‐41.
PsO = psoriasis.
Predictors of PsA• Involvement of certain body sites
– Scalp– Intergluteal areas (‘inverse / intertriginous’ psoriasis)
• Psoriatic nail lesions– Onycholysis– Nail pitting
• Younger age of psoriasis onset • Greater BSA involvement of psoriasis• Family history of psoriatic arthritis• All studies had limitations
– Case‐control studies, recall bias, possible misclassification bias (OA)
Wilson FC et al. Arthritis Rheum. 2009;61: 233‐239. Soltani‐Arabshahi R et al. Arch Dermatol. 2010;146:721‐726. Tey HL et al. J Dermatol. 2010;37:426‐430. Ogdie A, Gelfand JM. Curr Rheumatol Rep. 2015;17:64.
OA = osteoarthritis.
Clinical Features of PsA
Symptoms• Fatigue• Joint pain • Joint swelling• Morning stiffness
(joint stiffness) lasting >30 minutes
Peripheral joint disease• Joint tenderness• Joint swelling• Number of affected joints• Joint distribution
McArdle A, et al. Clin Rev Allergy Immunol. 2017 Jul 27. doi: 10.1007/s12016‐017‐8630‐7. Gladman D, et al. Ann Rheum Dis. 2005;64(Suppl 2): ii14–ii17.
Metabolic syndrome Diabetes
HypertensionHypercholesterolemia
Crohn’s,cutaneous
Neutrophilic dermatoses,Hidradenitis suppurativa
PsoriaticArthritis
Spondyloarthritis
Cardiovasculardisease
(MI/stroke)
Sleep
Chronic kidney disease
Gout
Mental health
Psoriasis(plaque, nail,inverse, scalp)
MI = myocardial infarction.
Rheumatoid Arthritis: Pathophysiology and Diagnosis
Rheumatoid Arthritis Pathogenesis
HLA = human leukocyte antigen; ACPAs = anti‐citrullinated protein antibodies; GI = gastrointestinal; TNF = tumor necrosis factor; IL = interleukin.
Pianta, S et al. Arthritis Rheumatol. 2017;69(5):964‐975. Peizek, C et al. Arthritis Rheumatol. 2017;69(6): 1176‐1186.
Genetic susceptibility (HLA‐DRB1, etc.)
Adaptive immunity and citrullination (ACPAs) occur due to:• Smoking• Gingivitis
Lymphocyte activationMacrophage activationNeutrophil activationDendritic cell activation
Release of cytokines (TNF/IL‐1/IL‐6/IL‐17)Interferon release
Synoviocytes
RA Pathobiology
B cell
MΦImmune complexes
Complement fixationAttract inflammatory
cell infiltrates
IL-2IFNγTNFIL-17
RANKL
Pannus
Articularcartilage
TNF, IL-1, IL-6,Metalloproteinases(MMPs)
IL-4IL-6IL-10
IL-6, TNF,IFNγ, IL-10,
Lymphotoxin
Plasma cell
Antigen-presentingCells– B cells– Dendritic cells– Macrophages
OsteoclastChondrocytes
Production of MMPs and other effector moleculesMigration of polymorphonuclear cells
Erosion of bone and cartilage
Rheumatoid factor,ACPAs
T cellAPC
Adapted from Smolen JS, Steiner G. Nat Rev Drug Discov. 2003;2;473‐488. Choy EH, Panayi GS. N Engl J Med. 2001;344:907‐916. Silverman GJ, Carson DA. Arthritis Res Ther. 2003;5(suppl 4):S1‐S6.
RA = rheumatoid arthritis; IL = interleukin; IFN = interferon; TNF = tumor necrosis factor; APC = antigen‐presenting cell; RANKL = receptor activator of nuclear factor‐κB ligand; ACPA = anti‐citrullinated protein antibody.
Joint capsule
Synovial membrane
Joint space
Cartilage
Synoviocytes
Bone
Osteoclast
Fibroblast‐like synoviocyteMacrophage
Dendritic cell
T cell
Plasma cell
B cell
Mast cell
Pannus
Neutrophils
Synoviocytes
15
Normal Joint vs Rheumatoid Synovitis
15Strand V, et al. Nat Rev Drug Discov. 2007;6(1):75‐92.
Aletaha D et al. Arthritis Rheum. 2010;62:2569‐2581.
Negative RF AND ACPA 0Low‐positive RF OR ACPA 2
3High‐positive RF OR ACPA
(0–1)
<6 weeks 0≥6 weeks 1
Normal CRP AND normal ESR 0Abnormal CRP OR abnormal ESR
1
Serology (0–3)
Symptom duration (0–1)
Acute‐phase reactants
Swollen/tender joints (0–5)
Patients with a score of ≥6have “definite” RA.
2010 ACR/EULAR RA Classification Criteria
1 large joint 02–10 large joints 11–3 small joints 24–10 small joints 3>10 joints 5
Composite Measures of Disease Activity
Yazici Y. Bull NYU Hosp Jt Dis. 2007;65(suppl 1):S25‐S28. Zatarain E, Strand V. Nat Clin Pract Rheumatol. 2006;2:611‐618. Pincus T et al. Rheum Dis Clin North Am. 2009;35:773‐778.
Outcome Measures in RAACR20/50/70 DAS28 SDAI CDAI RAPID
Patient function + +Patient pain + +Patient global + + + + +Physician global + + +# tender joints + + + +# swollen joints + + + +ESR or CRP + + +
DAS = Disease Activity Score; SDAI = Simplified Disease Activity Index; CDAI = Clinical Disease Activity Index; RAPID = Routine Assessment of Patient Index Data.
Measures of RA Disease Activity
Anderson J et al. Arthritis Care Res (Hoboken). 2012;64:640‐647. Singh JA et al. Arthritis Care Res (Hoboken). 2012;64:625‐639.
Categories of Disease ActivityInstrument Remission Low Moderate HighDAS28 <2.6 ≥2.6 to <3.2 ≥3.2 to ≤5.1 >5.1CDAI ≤2.8 >2.8 to 10.0 >10.0 to 22.0 >22.0RAPID 0 to 1.0 >1.0 to 2.0 >2.0 to 4.0 >4.0 to 10.0
SDAI ≤3.3 >3.3 to ≤11.0 >11.0 to ≤26.0 >26.0
Examples of Tools Measuring PsA
• Peripheral joints:– ACR joint count (TJC, SJC, VAS
pain, PtGA, PGA, HAQ, CRP or ESR)
– PsARC– DAS
• Spine / axial:– BASDAI– ASAS-N
• Enthesitis:– MASES index (Maastrict
Ankylosing Spondylitis Enthesitis Score)
– LEI
• Dactylitis:– LDI
• QOL:– SF36– PsAQoL– HAQ– Fatigue: FACIT– Work / WPAI– PSAID
– RAPID3, PtGA of arthritis, etc
NOTE: PsA Symptom Measurement can be performed by dermatologists in the clinic –On‐going work with IDEOM* ‐JF Merola
PsA Disease Measurement/Disease Activity
*This study used a modified CPDAI (for peripheral PsA only) which used a 3‐point scale for each limb (total of 12)**Includes # of tender joints, CRP, and patient assessment on two 1‐10 scales
Minimal Disease Activity RemissionMeasure(Range)
Optimal Cut‐Off
Sensitivity (%)
Specificity (%)
Optimal Cut‐Off
Sensitivity (%)
Specificity (%)
DAS28‐CRP(0.96‐8.79) ≤3.6 76 89 <2.4 72 89
DAS28‐ESR(0.49‐9.07) ≤3.6 73 89 <2.4 71 89
SDAI(0‐86) ≤11 79 89 <3.3 74 90
mCPDAI*(0‐12) ≤5 68 84 <2 69 85
DAPSA** ≤15 77 89 <4 73 89
PASDAS(0‐10) ≤3.6 76 86 <2.4 75 85
Criterion values and coordinates of the ROC curve for MDA and remission criteria.
Salaffi F, et al. BioMed Res Int. 2014(2014). 12 Pages
Psoriatic Arthritis: Treatment Options
Video: Psoriatic ArthritisTreatment Options
Not disease‐modifying• NSAIDs• Corticosteroid injections
• Corticosteroids (oral)
Traditional DMARDs• Methotrexate• Leflunomide• Sulfasalazine• Cyclosporine
Anti‐TNFa• Etanercept• Adalimumab• Infliximab• Golimumab• Certolizumab Nonpharmacologic
measures• PT and OT• Obesity control• Depression treatment• Cardiovascular risk factor mod
• Smoking cessation• Microbiome modification
Newer therapies• Ustekinumab (IL12/23)• Secukinumab (IL17A)• Abatacept (CTLA4‐Ig)• Apremilast (PDE4)• Ixekizumab (IL17)• Tofacitinib (JAK3)
In development• Brodalumab (IL17R)• Guselkumab (IL23)• Risankizumab (IL23)• Tildrakizumab (IL23)• Upadacitinib (JAK1)
PsA Treatment Options
NSA
IDs a
nd IA
I cortic
osteroids a
s ind
icated
DMARDs (MTX, SSZ, LFN), TNFi
or PDE4i
Biologics (TNFi, IL‐12/23i IL‐
17i) or PDE4i
Switch biologic (TNFi, IL‐12/23i
or IL‐17i)
Peripheral Arthritis
Physiotherap
y an
d NSA
IDs
NSAIDs only
TNFi, IL‐17i or IL‐12/23i*
Switch biologic (TNFi, IL‐17i orIL‐12/23i*)
No direct evidence for therapies in axial PsA:recommendations based on axial SpAliterature
Axial Disease
Physiotherap
y
NSAIDs
Biologics (TNFi, IL‐12/23i, IL‐17i) or PDE4i
Corticosteroid injections: consider on an individual basis due to potential for serious side effects; no clear evidence for efficacy
Switch biologic (TNFi, IL‐
12/23i, IL‐17i) or PDE4i
Enthesitis
Corticosteroid injections as ind
icated
NSAIDs
DMARDs (MTX, LEF, SSZ) or PDE4i
Biologics (TNFi, IL‐12/23i)
Switch biologic (TNFi, IL‐
12/23i, IL‐17i) or PDE4i
Dactylitis
Biologics (TNFi, IL‐12/23i, IL‐17i) or PDE4i
Topical or procedural
or DMARDs (CSA, LEF, MTX,
acitretin)
Switch biologic (TNFi, IL‐
12/23i, IL‐17i) or PDE4i
Nails
Topicalsas indicated
Topicals(keratolytics, steroids, vitamin D analogues, emollients, calcineurin)
Phototherapy or DMARDs (MTX, CSA, acitretin, fumaric acid
esters) or PDE4i
Biologics (TNFi, IL‐12/23i, IL‐17i) or
PDE4i
Switch biologics (TNFi, IL‐12/23i, IL‐17i) or
PDE4i
Skin
Which domains are involved?
Assess activity
, impa
ct, and
progn
ostic
factors
Standard therapeutic route Expedited therapeutic route
*Open‐label data available.White text identifies conditional recommendations for drugs without current regulatory approvals or where recommendations are based on abstract data only.MTX=methotrexate. SSZ=sulfasalazine. LFN=leflunomide. TNFi=tumor necrosis factor inhibitor. PDE4i=phosphodiesterase 4 inhibitor. CSA=cyclosporine A.
Coates LC, et al. Arthritis Rheumatol. 2016 May;68(5):1060‐71.
GRAPPA Treatment Schema for Active PsA
Traditional DMARDs
• Methotrexate
• Leflunomide
• Sulfasalazine
• Cyclosporine
TNFαI = TNF alpha inhibitor; MTX = methotrexate.
Kumar P, et al. Clin Med Insights Arthritis Musculoskelet Disord. 2013;6:35–43. Parida J, et al. World J Orthop. 2015;6(2):278–283. Eder L et al. Ann Rheum Dis.2014;73:1007‐11. Finzel S, et al. Ann Rheum Dis. 2013;72:1176‐81.
POSITIVES• Many years of use• Helpful in some cases• Inexpensive• Prevent antibody
generation, increase retention of TNFαI drugs (MTX)
NEGATIVES• Lack of high‐quality data• Suboptimal dosing• Not disease modifying
Methotrexate in PsA (MIPA) Trial
Kingsley GH et al. Rheumatology (Oxford). 2012; 51:1368‐1377.
Methotrexate goal of 15 mg/week
0
2
4
6
8
10 Swollen joint count
02468
10121416
0 3 6
Tender joint count
Months
0
10
20
30
40
50
60Patient global assessment*
Global Index OR (95%CI) P-valuePsARC 1.77 (0.97–3.23) 0.06ACR 20 2.00 (0.65–6.22) 0.23DAS 28 response 1.70 (0.90–3.17) 0.10
PsARC = PsA response criteria; OR = odds ratio; CI = confidence interval.*100‐mm visual analogue score (VAS).
MTX
Placebo
0 063 63
MIPA Trial: Skin
Kingsley GH et al. Rheumatology (Oxford). 2012; 51:1368‐1377.
MTX Placebo
Significant reduction in PASI 75 for MTX users: Adjusted treatment difference was −0.93 (95% CI −1.71, −0.15) P = 0.02
PASI 75 response rates were not significant (OR 1.26, 95% CI 0.58–2.72).
PASI 753.76
2.22
3.79
3.13
0
1
2
3
4
Baseline Follow up
Score
Tight Control in PsA Trial (TiCOPA)
Coates LC et al. Lancet. 2015;386:2489‐2498.
MTX+CyA or MTX+LEF
6259
44
33
0
10
20
30
40
50
60
70
ACR20 PASI75
Tight Control Standard
MTX
MTX+SSZ
Second aTNFa
aTNFa
SSZ = sulfasalazine; CyA = cyclosporine; LEF = leflunomide.
Respon
se at 4
8 wee
ks (%
)
Serious Adverse Events
Tight Control Standard CareDeaths 0 0
SAE 25 8
SAE related to drug 8 2
Blood/lymph systemCardiacGIHepatobiliaryImmune systemInfection/infestationInjury/poisoningMSK and CTDNeoplasmsNervous systemRenal/urinaryReproductive/breastRespiratory and thoracic
1152131401114
0020010212000
Coates L, et al. Lancet. 2015 Dec 19;386(10012):2489‐98
Leflunomide for PsA
Kaltwasser JP et al. Arthritis Rheum. 2004;50:1939‐1950.
20.1
14.5
18.5
15.5
0
5
10
15
20
25
30
35
40
Baseline Follow up
Tender joints
LEF Placebo
11.6
7.3
13.3
10.5
0
5
10
15
20
25
30
35
40
Baseline Follow up
Swollen joints
LEF Placebo
36.3
17.420
7.8
0
5
10
15
20
25
30
35
40
ACR20 PASI
LEF Placebo
P=0.014
P=0.048
Respon
se (%)
Joint c
ount
ACR 20; PASI
Not disease‐modifying• NSAIDs• Corticosteroid injections
• Corticosteroids (oral)
Traditional DMARDs• Methotrexate• Leflunomide• Sulfasalazine• Cyclosporine
Anti‐TNFa• Etanercept• Adalimumab• Infliximab• Golimumab• Certolizumab Nonpharmacologic
measures• PT and OT• Obesity control• Depression treatment• Cardiovascular risk factor mod
• Smoking cessation• Microbiome modification
Newer therapies• Ustekinumab (IL12/23)• Secukinumab (IL17A)• Abatacept (CTLA4‐Ig)• Apremilast (PDE4)• Ixekizumab (IL17)• Tofacitinib (JAK3)
In development• Brodalumab (IL17R)• Guselkumab (IL23)• Risankizumab (IL23)• Tildrakizumab (IL23)• Upadacitinib (JAK1)
PsA Treatment Options
TNF Inhibitors in PsA
Mease PJ. Rheum Dis Clin North Am. 2015;41:723‐738.
59 58 58
52
58
1511
14
8
24
0
10
20
30
40
50
60
70
ETA IFX ADA GOL CER
TNFi Placebo
1115
20 18
25
0 1 1 1 3
0
10
20
30
40
50
60
70
ETA IFX ADA GOL CER
TNFi Placebo
ACR 20 ACR 70
TNFi = tumor‐necrosis‐factor inhibitor; ETA = etanercept; IFX = infliximab; ADA = adalimumab; GOL = golimumab; CER = certolizumab.
Respon
se
Respon
se
Not disease‐modifying• NSAIDs• Corticosteroid injections
• Corticosteroids (oral)
Traditional DMARDs• Methotrexate• Leflunomide• Sulfasalazine• Cyclosporine
Anti‐TNFa• Etanercept• Adalimumab• Infliximab• Golimumab• Certolizumab Nonpharmacologic
measures• PT and OT• Obesity control• Depression treatment• Cardiovascular risk factor mod
• Smoking cessation• Microbiome modification
Newer therapies• Ustekinumab (IL12/23)• Secukinumab (IL17A)• Abatacept (CTLA4‐Ig)• Apremilast (PDE4)• Ixekizumab (IL17)• Tofacitinib (JAK3)
In development• Brodalumab (IL17R)• Guselkumab (IL23)• Risankizumab (IL23)• Tildrakizumab (IL23)• Upadacitinib (JAK1)
PsA Treatment Options
IL‐12 receptor IL‐23 receptor
TH1 cell signaling TH17 cell signaling
Ustekinumab: IL12/23 InhibitorTargets p40 Subunit
p40 p40p35 p19
Koutruba N, et al. Ther Clin Risk Manag. 2010;6:123‐41.
Ustekinumab: Efficacy in PsA
McInnes IB et al. Lancet. 2013;382:780‐789. Ritchlin C et al. Ann Rheum Dis. 2014;73:990‐999.
42.4 43.7
22.820.2
0
10
20
30
40
50
60
70
PSUMMIT‐1 PSUMMIT‐2
ACR 20
UST 45mg Placebo
57.2
51.3
11
5
0
10
20
30
40
50
60
70
PSUMMIT‐1 PSUMMIT‐2
PASI 75
UST 45mg Placebo
% %
UST = ustekinumab.
IL17RA IL17RCIL17RA IL17RAIL17RCIL17RC
IL‐17A/ IL‐17FIL‐17FIL‐17 A
Anti‐IL17
Anti‐IL17
Anti‐IL17RA
SecukinumabIL17Ai
IxekizumabIL17Ai
BrodalumabIL17RAi
IL17 Inhibitors
Ixekizumab: ACR 20/50/70 Response80 mg Q4W; 24‐Week Response
Ixekizumab Prescribing Information. Eli Lilly and Company. December, 2017.
Respon
se (%
)
*P<0.05 vs Placebo
5853
4035
23 22
0
10
20
30
40
50
60
70
Anti‐TNF Naïve Anti‐TNF ExperiencedACR 20 ACR 50 ACR 70
*
*
*
*
*
*
IL17A Inhibitor: Ixekizumab in PsA
Mease PJ et al. Ann Rheum Dis. 2017;76:79‐87.
57* 60*52*
31
58*62*
57*
30
010203040506070
IXE Q4W IXE Q2W ADA Q2W Placebo
SPIRIT1‐ACR 20
Respon
ders (%
)
Weeks Weeks Weeks
PASI 75 PASI 90 PASI 100A B C100
242016
Placebo IXE Q4W IXE Q2W ADA Q2W
12840
806040200
100
24201612840
806040200
100
24201612840
806040200
IXE = ixekizumab; ADA = Adalimumab.
%
12 Weeks
24 Weeks
*P<0.05 vs Placebo
Secukinumab: Efficacy in PsA
Mease PJ et al. N Engl J Med. 2015;373:1329‐1339. McInnes IB et al. Lancet. 2015;386:1137‐1146.
50 51
17.315
0
10
20
30
40
50
60
70
FUTURE‐1 FUTURE‐2
ACR 20
SEC 150 Placebo
61.1
48
8.3
16
0
10
20
30
40
50
60
70
FUTURE‐1 FUTURE‐2
PASI 75
SEC 150 Placebo
SEC = secukinumab.
% Respo
nse
% Respo
nse
Secukinumab: FUTURE 5Reduced Progression of Joint Structural Damage
Mease P, et al. Presented as a late‐breaker at the 2017 ACR/ARHP Annual Meeting. November 7, 2017.
SEC = secukinumab; LD = with Loading Dose; mTSS = modified total van der Heijde Sharp score
88%
80%84%
74%
30%
40%
50%
60%
70%
80%
90%
100%
300 mg (LD) 150 mg (LD) 150 mg Placebo
% with
No Worsening
of Joint Dam
age
on m
TSS
*
**
ApremilastPhosphodiesterase 4 inhibitor
PDE4 = phosphodiesterase 4; cAMP = cyclic adenosine monophosphate; PKA = protein kinase A; NF‐κB = nuclear factor‐kappa B; ATF‐1 = ; activating transcription factor 1; CREB = cAMP responsive element binding (protein); IFN = interferon.
PDE4
Accumulation of cAMP
NF‐B
CREB
ATF‐1
Decreases inflammatory cytokines: TNF, IFNɣ, IL12, IL17, IL22, IL23
PKA
N
NH
HS OO
O
O
O
OO
Perez‐Aso M, et al. Arthritis Res Ther. 2015;17:249.
Apremilast for PsA: PALACE Trials
Kavanaugh A et al. Ann Rheum Dis. 2014;73:1020‐1026. Cutolo M et al. J Rheumatol. 2016;43:1724‐1734. Edwards CJ et al. Ann Rheum Dis. 2016;75:1065‐1073.
40
32.1
41
19 18.9 18
0
5
10
15
20
25
30
35
40
45
PALACE1 PALACE2 PALACE3
ACR 20
APR 30 BID Placebo
P<0.001
P=0.006
21 21
4.6
8
0
5
10
15
20
25
30
35
40
45
PALACE1 PALACE3
PASI 75
APR 30 BID Placebo
P<0.05P=0.004
Apremilast is not preferred in erosive disease. Its ability to prevent joint injury is unproven.
P<0.001
% %
Abatacept: Phase III Trial(FDA Approved for PsA on 7‐6‐2017)
Mease PJ et al. Ann Rheum Dis. 2017;76:1550‐1558.
39.4
26.7
22.319.6
0
5
10
15
20
25
30
35
40
45
ACR20 PASI50
ABTPlacebo
%
P<0.001
ABT = abatacept.Note: Possibly more refractory population – 60% had prior anti‐TNF exposure. Benefits (but not equal responses) were seen regardless of exposure.
50.5
60.6
51.9
33.3
49.647
23.7
0
10
20
30
40
50
60
70
Tofa‐5 Tofa‐10 ADA Placebo
Tofacitinib for PsA
Mease PJ et al. ACR Annual Meeting 2016, Abstract 2983 (http://acrabstracts.org/abstract/efficacy‐and‐safety‐of‐tofacitinib‐an‐oral‐janus‐kinase‐inhibitor‐or‐adalimumab‐in‐patients‐with‐active‐psoriatic‐arthritis‐and‐an‐inadequate‐response‐to‐conventional‐synthetic‐dmards‐a‐randomized/). Gladman D et al. ACR Annual Meeting 2016 Abstract 10L (http://acrabstracts.org/abstract/efficacy‐and‐safety‐of‐tofacitinib‐an‐oral‐janus‐kinase‐inhibitor‐in‐patients‐with‐active‐psoriatic‐arthritis‐and‐an‐inadequate‐response‐to‐tumor‐necrosis‐factor‐inhibitors‐opal‐beyond‐a‐randomize/).
42.744.3
39
14.6
21.3
43.2
14
0
5
10
15
20
25
30
35
40
45
50
Tofa‐5 Tofa‐10 ADA Placebo
ACR 20 PASI 75TNF naïve
TNF IR
TNF naïve
TNF IR
% %
IR = inadequate response.
Not disease‐modifying• NSAIDs• Corticosteroid injections
• Corticosteroids (oral)
Traditional DMARDs• Methotrexate• Leflunomide• Sulfasalazine• Cyclosporine
Anti‐TNFa• Etanercept• Adalimumab• Infliximab• Golimumab• Certolizumab Nonpharmacologic
measures• PT and OT• Obesity control• Depression treatment• Cardiovascular risk factor mod
• Smoking cessation• Microbiome modification
Newer therapies• Ustekinumab (IL12/23)• Secukinumab (IL17A)• Abatacept (CTLA4‐Ig)• Apremilast (PDE4)• Ixekizumab (IL17)• Tofacitinib (JAK3)
In development• Brodalumab (IL17R)• Guselkumab (IL23)• Risankizumab (IL23)• Tildrakizumab (IL23)• Upadacitinib (JAK1)
PsA Treatment Options
Rheumatoid Arthritis: Treatment Options
The Principles of Treating to Target
• Treating to target by measuring disease activity and adjusting therapy accordingly will result in better patient outcomes.
• The primary target for treatment should be clinical remission (CR), defined as the absence of signs and symptoms of significant inflammatory disease activity.
• In some cases, low disease activity (LDA) may be an acceptable treatment goal, particularly in patients with long‐standing established disease.
Smolen JS et al. Ann Rheum Dis. 2010;69:631‐637.
Oral non‐biologicsMethotrexateSulfasalazineHydroxychloroquineLeflunomideAzathioprineCyclosporineTacrolimusCyclophosphamide
Prednisone
Selective cytokine inhibitors
TNF inhibitorsEtanerceptInfliximabAdalimumabCertolizumabGolimumab
IL‐1 inhibitorsAnakinra
IL‐6 inhibitorTocilizumab
B cell cepletionRituximab
T cell co‐stimulation blockadeAbatacept
JAK inhibitionTofacitinib
Disease‐Modifying Pharmacotherapies for RA
Classes of Biologics for RA
*Baricitinib is not FDA‐approved for RA.Woodrick RS, Ruderman EM. Nat Rev Rheumatol. 2011;7:639‐652. Shuai K, Liu B. Nat Rev Immunol. 2003;3:900‐911.
TNF inhibitors
Other biologic agents
Infliximab
TNFAdalimumab
Etanercept
Certolizumab pegol
Golimumab
Tocilizumab
IL‐6RIL‐1R
AnakinraIL‐1 IL‐6
IL‐6 signaling
Antigen
MHC
APC
IL‐1 signaling
B cell
RituximabT‐cell receptor
B‐cell depletionCo‐stimulatory signal
T cell
Abatacept
CD80or CD86 CD28
CD20Cytokine receptor
JAK JAK
TofacitinibBaricitinib*
JAK inhibitors
2015 ACR RA Treatment Recommendations for Early RA
Singh JA et al. Arthritis Rheumatol. 2016;68:1‐26. (Also published in Arthritis Care Res [Hoboken]. 2016;68:1‐25.)
DMARD monotherapyb
DMARD monotherapyb
Moderate or high disease activityb,c
T2Ta
Low disease activity
Moderate or high disease activity
DMARD‐naïve early RA
aTreatment target should ideally be LDA or remission. bConsider using short‐term glucocorticoids (GCs) (<3 months) for flares. cConsider adding low‐dose GCs (≤10 mg/day of prednisone or equivalent) in patients with moderate or high disease activity when starting DMARDs and in patients with DMARD failure or biologic failure.
2015 ACR RA Treatment Recommendations for Early RA (Continued)
Singh JA et al. Arthritis Rheumatol. 2016;68:1‐26. (Also published in Arthritis Care Res [Hoboken]. 2016;68:1‐25.)
Combination traditional DMARDsb,c orTNFi +/– MTXb,c or
non‐TNF biologic +/– MTXb,c
See established RA algorithm
T2Ta
Moderate or high disease activityb,c
Moderate or high disease activityb,c
aTreatment target should ideally be LDA or remission. bConsider using short‐term glucocorticoids (GCs) (<3 months) for flares. cConsider adding low‐dose GCs (≤10 mg/day of prednisone or equivalent) in patients with moderate or high disease activity when starting DMARDs and in patients with DMARD failure or biologic failure.
Are Some TNFis Better Than Others?
EXXELERATE™ Trial: ADA + MTX vs CZP + MTX in MTX‐IR Patients
• MTX IR patients (n = 915)
• Superiority endpoint: ACR20/50/70 response rates NOT MET
CZP = certolizumab pegol.
NCT01500278 (https://clinicaltrials.gov/ct2/show/NCT01500278?term=NCT01500278&rank=1). www.ucb.com/presscenter/News/article/UCB‐Announces‐Results‐from‐First‐Head‐to‐Head‐study‐of‐Cimzia‐certolizumab‐pegol‐and‐Humira‐adalimumab‐in‐Bio‐Na‐ve‐Rheumatoid‐Arthritis‐Patients
Head‐to‐headcomparison
ACR ResponseWeek 12 ACR 20 ACR 50 ACR 70
LDAS at 2 Years
CZP NR ADA 40 17 8 35.5%
ADA NR CDP 44 23 11 33.5%
TNF‐Inhibitors vs. Non‐TNF Inhibitors: Comparative Data
100
80
40
20
0
0AC
R respon
se ra
te (%
)Visit day
60
ADASC ABA
64.8%
63.4%ACR20
64.8%
63.4%ACR50
64.8%
63.4%ACR70
85 197 36529 141 253 309
AMPLE Study: Outcomes
Weinblatt ME et al. Arthritis Rheum. 2013;65:28‐38.
100
80
40
20
0
ABA SC ADA SC
ACR2
0 Re
spon
se Rate (%
)
Estimate of difference (95% CI) between groups was 1.8 (–5.6 to 9.2);intent‐to‐treat, confirmed with per protocol populations
64.8 63.4
206/318 208/328
60
Primary endpoint:ABA SC is non‐inferior to ADA SC
Comparable efficacy and kinetics of response:ACR scores over 1 year
• No difference in safety• No difference in radiographic progression• ADA was more likely to be discontinued due to adverse events (3.0% vs 1.3%)
LOCF used for TJC and SJC. ESR and patient's global assessment of disease activity VAS, if ESR = 0, then ESR = 1 is substituted into the DAS28 calculation to enable a nonmissing DAS28.
ADACTA DAS28: Mean over Time
Gabay C et al. Lancet. 2013;381:1541‐1550.
8
7
6
4
2
1
0
DAS2
8 5
3
Baseline 4 8 12 16 20 24
Week
TZC 8 mg/kg + PBO (SC) (N =163)ADA 40 mg + PBO (IV) (N = 162)
Head‐to‐head comparison
JAK Inhibitors and Signaling by Type I/II Cytokine Receptors (Tofacitinib and Baricitinib)
γc familyIL‐2, etc.
GH,Epo,
GM‐CSFIL‐6
familyIL‐12,IL‐23
INF‐γ
Tofacitinib + + +Baricitinib + + + + +
JAK‐independent cytokine signaling: IL‐1, IL‐17, IL‐18, TGF‐β, TNFTofacitinib in vitro selectivity JAK3, JAK1>JAK2>>Tyk2Baricitinib in vitro selectivity JAK1, JAK2 >Tyk2>>JAK3
Furumoto Y, et al. BioDrugs. 2013;27:431‐8.
ORAL STANDARD: Outcomes at 6 Months
van Vollenhoven RF et al. N Engl J Med. 2012;367:508‐519.
DAS28‐4 (ESR) at month 6
11 / 177 13 / 178
16
12
8
4
0
NRI (without advancement penalty)
6.2 7.3
HAQ‐DI improvement at month 3
‐0.8
Placebo
ADA 40 mgTFA 5 mg
1 / 92
DAS28‐4(ESR) <2.6
(% of p
atients)
16
12
8
4
0
NRI (with advancement penalty)
6.2 6.7
11 / 177 12 / 178
1.1
Chan
ge in
HAQ‐DI Score
from
Baseline
(points) –0.24
–0.55–0.49
0.0
‐0.2
‐0.4
‐0.6
Head‐to‐headcomparison
RA‐BEAM: Efficacy
Taylor PC et al. Arthritis Rheumatol. 2015;67(suppl 10):abstract 2L.
PlaceboBARI 4 mgADA
Week 12 Week 24
Patie
nts (NRI)(%
)
vs placebo: ***P≤0.001; ** P≤0.01; * P≤0.05. vs adalimumab: ++ P≤0.01; + P≤0.05.
ACR20 ACR50 ACR70 ACR20 ACR50 ACR70
80
60
40
20
0
+***70
+***74
+***30
+***19
++***45
***61
***66
***35
***51 ***
45
***22
***13
5
17
4037
19
8
Non‐TNF Options for MTX‐IR: Summary
• With MTX– ABA vs ADA is neutral (AMPLE)1
– Phase III—TFA 5 mg bid over ADA (ORAL STANDARD)2
• ACR20 response rates were 51.5% with tofacitinib 5 mg, 47.2% with ADA, and 28.3% with placebo.
• No significant differences in DAS remission
– Phase III—BARI*over ADA (RA‐BEAM)3
• Without MTX– TCZ vs ADA favored TCZ (ADACTA)4
• ACR50 of 47.2 vs 27.8%
– Sarilumab* vs ADA (MONARCH)5
1. Schiff M et al. Ann Rheum Dis. 2014;73:86‐94. 2. van Vollenhoven RF et al. N Engl J Med. 2012;367:508‐519. 3. Taylor PC et al. Arthritis Rheumatol. 2015;67(suppl 10):abstract 2L. 4. Gabay C et al. Lancet. 2013;381:1541‐1550. 5. NCT02332590 (https://clinicaltrials.gov/ct2/show/NCT02332590?term=NCT02332590&rank=1).
*Baricitinib and sarilumab are not FDA‐approved for RA.
When a TNFi Fails
Options After TNF Inhibitor Failure (Partial List)
• Triple therapy– RACAT (ETA → TT)1
• Second TNF:– EXXELLERATE (ADA ↔ CDP in nonresponders)2
– GO‐FORWARD (TNF → GLM)3
– OPPOSITE (TNFIR → TNF)4
• Change MOA– REFLEX (TNFIR → RTX)5
– RADIATE (TNFIR → TCZ)6
– ATTAIN (TNFIR → ABA)7
– ORAL Step (TNF IR → TFA)8
– BEACON (TNF IR → Bari)9
• Multiple options:– French ROC (rotation of TNFi or change of biologic)10
1. O’Dell JR et al. N Engl J Med. 2013;369:307‐318. 2. NCT01500278. 3. Keystone EC et al. J Rheumatol. 2016;43:298‐306. 4. Furst DE et al. Ann Rheum Dis. 2007;66:893‐899. 5. Cohen SB et al. Arthritis Rheum. 2006;54:2793‐2806. 6. Emery P et al. Ann Rheum Dis. 2008;67:1516‐1523. 7. Genovese MC et al. N Engl J Med. 2005;353:1114‐1123. 8. Burmester GR et al. Lancet. 2013;381:451‐460. 9. Genovese MC et al. N Engl J Med. 2016;374:1243‐1252. 10. Gottenberg J et al. Arthritis Rheumatol. 2015;67(suppl 10): abstract 3110.
2015 ACR/2016 EULAR GuidelinesKey Principles
• Perform disease activity measurements and functional assessments frequently.
• Simplification of therapy in patients with LDA or remission at the physician’s discretion
• Arbitrary switching based on payer/insurance is not recommended.
• Patients at risk of persistent arthritis should start DMARDs within 3 months, even if classification criteria are not fulfilled.
• Oral CS can be added at the lowest effective dose and tapered.
• Aim for remission within 3 months.
• Maximize non‐pharmacologic interventions (eg, PT/OT, smoking cessation, dental care, weight control, vaccination updates) patient education.
Singh JA et al. Arthritis Rheumatol. 2016;68:1‐26. (Also published in Arthritis Care Res [Hoboken]. 2016;68:1‐25.). Combe B. Ann Rheum Dis. 2016;75(suppl 2):44 (abstract SP0183).
Patient Satisfaction
Patient Satisfaction
Mercy KM et al. JAMA. 2014;312:2676‐2677. Smolen JS et al. Ann Rheum Dis. 2010;69:631‐637.
• Patient satisfaction is rarely incorporated in practice guidelines.
• Studies rely on clinician‐centered measures to determine treatment adequacy.
• Patient satisfaction is an important consideration, linked with: – Patient adherence to therapy – Treatment outcomes
• Satisfaction contributes to responses in HRQoL indices (e.g., DLQI)
• Skin clearance and joint preservation matter to patients– E.g. 52.3% and 45.5% of pts are dissatisfied with PsO/PsA treatment
• T2T by measuring disease activity and adjusting therapy will result in better patient outcomes
DLQI = Dermatology Life Quality Index.
• Maintain patient motivation and engagement in care.
• Understand/explore reasons for declines in adherence.
• Set up realistic expectations.
• Take a health literate approach to prescribing and educating patients.
Building a trusting one‐on‐one relationship with the patient is essential for long‐term management.
Communication in Practice
Thank You!
Biologic Agents in Rheumatology: A Virtual Reality Tour through Psoriatic Arthritis and Rheumatoid Arthritis
Additional Reading
1. Cantini F, et al. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Semin Arthritis Rheum. 2017;47(2):183-92.
2. Cantini F, et al. Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. Semin Arthritis Rheum. 2016;45(5):519-32.
3. Coates L, et al. Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same? Semin Arthritis Rheum. 2016;46(3):291-304.
4. Jafri K, et al. Incidence and management of cardiovascular risk factors in psoriatic arthritis and rheumatoid arthritis: A population-based study. Arthritis Care Res (Hoboken). 2017;69(1):51-57.
5. Lauper K, et al. Incidence and prevalence of major adverse cardiovascular events in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. Arthritis Care Res (Hoboken). 2018 Apr 2. doi: 10.1002/acr.23567. [Epub ahead of print]
6. Lopez-Gonzalez R, et al. Adherence to biologic therapies and associated factors in rheumatoid arthritis, spondyloarthritis and psoriatic arthritis: a systematic literature review. Clin Exp Rheumatol. 2015;33(4):559-69.
7. Lubrano E, et al. Clinical remission in rheumatoid arthritis and psoriatic arthritis. Clin Exp Rheumatol. 2018 Mar 16. [Epub ahead of print].
8. Madan J, et al. Consensus decision models for biologics in rheumatoid and psoriatic arthritis: Recommendations of a multidisciplinary working party. Rheumatol Ther. 2015;2(2):113-25.
9. Nas K, et al. Comorbidities in patients with psoriatic arthritis: a comparison with rheumatoid arthritis and psoriasis. Int J Rheum Dis. 2015;18(8):873-9.
10. Ogdie A, et al. Cause-specific mortality in patients with psoriatic arthritis and rheumatoid arthritis. Rheumatology (Oxford). 2017;56(6):907-11.
11. Roubille C, et al. Evidence-based recommendations for the management of comorbidities in rheumatoid arthritis, psoriasis, and psoriatic arthritis: Expert opinion of the Canadian Dermatology-Rheumatology Comorbidity Initiative. J Rheumatol. 2015;42(10):1767-80.
12. Veale D, et al. What makes psoriatic and rheumatoid arthritis so different? RMD Open. 2015;1(1):e000025.
13. Verheul M, et al. Biomarkers for rheumatoid and psoriatic arthritis. Clin Immunol. 2015;161(1):2-10.
Psoriatic/Rheumatoid Arthritis Resources: Associations/Foundations American Academy of Dermatology
https://www.aad.org/ American College of Rheumatology
https://www.rheumatology.org/ Rheumatology Research Foundation
https://www.rheumresearch.org/ Arthritis Foundation
https://www.arthritis.org/ World Health Organization
http://www.who.int/chp/topics/rheumatic/en/